Evidence map›Paper›PMID 27433858›Full record

Trial reportMenopause (New York, N.Y.)2016

Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study.

Elizabeth A Hibler, James Kauderer, Mark H Greene, Gustavo C Rodriguez, David S Alberts

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Menopause (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Updates and evolving care paradigms for pre-menopausal patients with endometrial cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
    Review
  5. Article
  6. Review
  7. Bone Health for Gynaecologists.Medicina (Kaunas, Lithuania) · 2025
    Review
  8. Article
  9. Spanish Society of Medical Oncology recommendations for comprehensive assessment and care of cancer survivors' needs.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  10. Molecular and pathologic data to guide selection of patients with endometrioid endometrial cancer for ovarian preservation.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Demographic shifts associated with implementation of evidence-based guidelines for ovarian conservation in patients with endometrioid endometrial cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022
    Article
  15. Article
  16. Loss of bone density and bone strength following premenopausal risk-reducing bilateral salpingo-oophorectomy: a prospective controlled study (WHAM Study).Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
    Article
  17. Review
  18. Effect of herbal extract Eurycoma longifolia (PhystaBMC complementary medicine and therapies · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elizabeth A Hibler1Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 2Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 3NRG Oncology/Gynecologic Oncology Group, Statistics and Data Center, Roswell Park Cancer Institute, Buffalo, NY 4National Cancer Institute, Clinical Genetics Branch, Bethesda, MD 5Northshore University Health, Kellogg Cancer Center, Evanston, IL 6University of Arizona, University of Arizona Cancer Center, Tucson, AZ.
James Kauderer
Mark H Greene
Gustavo C Rodriguez
David S Alberts

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Elaina Harper · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
GYNECOLOGIC ONCOLOGY GROUP HEADQUARTERSU10CA027469 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI DISAIA, PHILIP J. · 1985 to 2013
$132.6M
GYNECOLOGIC ONCOLOGY GROUP STATISTICAL OFFICEU10CA037517 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI BLESSING, JOHN A · 1985 to 2013
$67.4M
GYNECOLOGIC ONCOLOGY GROUPU10CA101165 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI DISAIA, PHILIP J. · 2003 to 2014
$43.1M
Cancer Prevention and Control Translational ResearchR25CA078447 · NCI · UNIVERSITY OF ARIZONA · PI ALBERTS, DAVID SAMUEL · 1998 to 2014
$7.6M
Vanderbilt Training Program in Molecular and Genetic Epidemiology of CancerR25CA160056 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEIMBURGER, DOUGLAS CORBETT, SHU, XIAO-OU · 2012 to 2016
$2.1M
NCI NIH HHS P30 CA060553NCI NIH HHS R25 CA078447NCI NIH HHS R25 CA160056NCI NIH HHS U10 CA027469NCI NIH HHS U10 CA037517NCI NIH HHS U10 CA101165NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA189867
6 · The paper itself

Abstract

objectiveWomen undergoing premenopausal oophorectomy for a variety of reasons, including to reduce ovarian or breast cancer risk were evaluated for accelerated bone loss.

methodsThe Gynecologic Oncology Group (GOG)-0215 randomized phase-II trial of zoledronic acid was initiated to determine if postoophorectomy bisphosphonate therapy could prevent this bone loss. The study was closed after slow accrual prevented evaluation of the primary study endpoint. We analyzed changes in bone mineral density (BMD) among the 80 women randomized to the observation arm of this study, as measured 3, 9, and 18 months postenrollment.

resultsThe mean change in BMD from baseline to 18 months was -0.09 (95% CI, -0.12 to -0.07), -0.05 (95% CI, -0.07 to -0.03), and -0.06 (95% CI, -0.07 to -0.05) g/cm across the lumbar spine, right hip, and left hip, respectively. This represents a BMD decrease of -8.5% for the lumbar spine and -5.7% for both the right and left hips from baseline to 18 months' observation.

conclusionsThese results demonstrate that premenopausal women undergoing oophorectomy clearly experience bone loss, an adverse effect of oophorectomy, which requires attention and active management. BMD should be monitored postoophorectomy, and treated per standard practice guidelines. Future studies will be required to determine if early treatment can mitigate fracture risk, and to test promising therapeutic interventions and novel prevention strategies, such as increased physical activity or alternative medications, in randomized trials.

Indexed as

PremenopauseAdultBone DensityBone Density Conservation AgentsBreast NeoplasmsDiphosphonatesFemaleHumansImidazolesMiddle AgedOsteoporosisOvarian NeoplasmsOvariectomyRisk FactorsZoledronic AcidBone Density Conservation AgentsDiphosphonatesImidazolesZoledronic Acid

Identifiers

PMID27433858
PMCPMC5079806

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.